enVVeno Medical Corporation reported a net loss of $19.5 million for the fiscal year ending December 31, 2025, a decrease of 11% from the previous year's loss of $21.8 million. The reduction in losses was attributed to a $2.9 million decrease in operating expenses, which included a 19% reduction in research and development costs, primarily due to lower expenses related to the VenoValve study. The company continues to operate without generating significant revenue, as it is still in the developmental stage of its product candidates, particularly the enVVe System, which is designed to treat severe Chronic Venous Insufficiency (CVI).
In terms of strategic developments, enVVeno Medical has shifted its focus from the VenoValve, which received a not-approvable letter from the FDA in August 2025, to the enVVe System, a next-generation, non-surgical venous valve product. The company has completed pre-clinical testing for the enVVe System and is in discussions with the FDA regarding a pivotal trial expected to commence in 2026. The company operates from a 14,507 square foot manufacturing facility in Irvine, California, which is ISO 13485-2016 certified for the design and manufacturing of tissue-based implantable medical devices.
As of December 31, 2025, enVVeno Medical had a cash balance of $3.1 million and investments totaling $25.1 million, providing a total of $28.2 million in cash and investments. The company anticipates a cash burn rate of approximately $4 million to $5 million per quarter in 2026, which may necessitate additional capital raises to sustain operations and fund product development initiatives. The company has historically funded its operations through capital raises and will need to continue this practice to meet its future obligations.
The company has also undergone organizational changes, including the appointment of Jennifer Bright as Chief Financial Officer in May 2025. As of March 24, 2026, enVVeno Medical had 655,521 shares of common stock outstanding, following a one-for-thirty-five reverse stock split that took effect on January 20, 2026. The reverse stock split was part of a strategy to regain compliance with Nasdaq's minimum bid price requirement, which the company successfully achieved in early February 2026.
Looking ahead, enVVeno Medical's future performance will largely depend on the successful regulatory approval and commercialization of its product candidates, particularly the enVVe System. The company acknowledges the inherent risks and uncertainties associated with the medical device industry, including the potential for further regulatory challenges and the need for effective market penetration strategies to achieve acceptance among healthcare providers and patients.
About enVVeno Medical Corp
enVVeno Medical Corporation is a late-stage medical device company developing bioprosthetic solutions for venous disease, primarily focusing on chronic venous insufficiency. Its flagship products, VenoValve and enVVe, are designed as surgical and non-surgical venous valves to treat severe deep venous conditions. The company aims to improve patient outcomes and reduce healthcare costs through innovative, tissue-based implantable devices targeting a large, underserved market.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.